



2016 Board of Trustees Executive Committee Biographical Information

Judy Black, Chair: Ms. Black is a Policy Director in the Government Relations Department of Brownstein, Hyatt, Farber and Schreck. She is recognized as one of the premier Republican lobbyists in Washington, DC, while also enjoying bipartisan relationships and respect throughout the federal government. For over a decade Ms. Black has helped Fortune 500 companies, leading non-profits, and industry trade groups navigate and participate in the public policy process. Prior to joining the firm, Ms. Black co-owned and operated Evans and Black Capitol Strategies, a DC-based legislative and lobbying firm. Ms. Black has also served as the senior vice president of government relations for Ticketmaster, where she established the company's government relations office and directed all federal and state government affairs. Additionally, she held the position of senior vice president of government relations for the International Council of Shopping Centers.

Ms. Black served in the White House from 1987 to 1989, where she was the Special Assistant to President Reagan for Intergovernmental Affairs. In that capacity, she was the liaison to the nation's governors and other statewide elected officials. Ms. Black has also held positions as the secretary for the Republican National Convention (1984), a Reagan delegate at the 1984 Republican National Convention, and treasurer for the National Federation of Republican Women (1986-1987). In the 2008 presidential campaign, she volunteered as cochairman of Women for McCain. Acknowledging her experience, Ms. Black was asked in the 2012 presidential campaign to volunteer as Chairman of Women for Romney in Washington, DC.

Robert Gagel, MD, President: Dr. Gagel is a Professor of Medicine at MD Anderson Cancer Center and an Adjunct Professor in the Department of Cell Biology at Baylor College of Medicine. A medical expert in Multiple Endocrine Neoplasia Type 2 (MEN2) and medullary thyroid carcinoma, as well as bone biology and calcitonin, Dr. Gagel was appointed Professor and Chief of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center in 1991 and Chairman of the Department of Medical Specialties in 1995. In 2001, he assumed the position of Head, Division of Internal Medicine. Dr. Gagel stepped down from that role in December 2014, transitioning to the Department of Endocrine Neoplasia and Hormonal Disorders in January 2015 where he will continue his research and patient care.

He also developed and worked with Rolanette and Berdon Lawrence (also an NOF Board Member) to establish the Bone Program of Texas, a collaborative program of the Baylor College of Medicine and the University of Texas M.D. Anderson Cancer Center and University of Texas Health Science Center – Houston, where he currently serves as Director. Dr. Gagel and colleagues developed and validated strategies for early detection of medullary thyroid carcinoma and pheochromocytoma through a 15-year series of articles published in the *New England Journal of Medicine*. While subsequently pursuing a laboratory fellowship at Harvard Medical School and The Harvard School of Public Health, Dr. Gagel was introduced to bone biology and the physiology of calcitonin, where he has made significant contributions, including studies of transcriptional regulation of the calcitonin gene, recognition of one of the elements that regulates alternative RNA processing of the calcitonin gene, and most recently the creation of a mouse in which the calcitonin gene has been deleted.

Kenneth G. Saag, MD, MSc, Vice President: Dr. Saag is Jane Knight Lowe Professor of Medicine, Division of Clinical Immunology and Rheumatology, at the University of Alabama at Birmingham (UAB) School of Medicine, and Professor of Epidemiology, at the UAB School of Public Health. He is the founding Director of the Deep South Musculoskeletal (DSM) Center for Education and Research on therapeutics (CERTs), and Associate Director of the Multidisciplinary Clinical Research Center (NIAMS P60). Dr. Saag is also Director of the UAB Center for Outcomes and Effectiveness Research and Education (COERE), a university-wide supported interdisciplinary research center. He is the director of the Agency for Healthcare, Research and Quality (AHRQ) supported UAB T32 in Health Services Research. He is a practicing rheumatologist and outcomes researcher with expertise in musculoskeletal disorders (MSD) and pharmacoepidemiology, and has a clinical focus in bone health. He is the only rheumatologist on the Board of Directors of the National Osteoporosis Board or Trustees.

Dr. Saag is experienced in designing and conducting clinical trials in the therapeutics of MSD and in population-based investigations, working with large databases, and quality indicator development. He is has served on the FDA Arthritis Advisory Committee and co-chaired the American Medical Association (AMA) Physician Consortium for Performance Improvement on Osteoporosis. He is on the editorial board of *Annals of Internal Medicine*, Associate Editor for *Arthritis Research and Therapy*, and serves as the American College of Rheumatology (ACR), Quality of Care Committee Chair. Dr. Saag has previously chaired the Arthritis Foundation Clinical, Therapeutics and Outcomes Study Section, has served on several NIH study sections, IOM Committees, National Committees to develop both arthritis and osteoporosis guidelines, the Musculoskeletal Workgroup of the Cochrane Collaboration, and the NCQA workgroup on Arthritis Quality Indicators. In addition to his CERTs, Dr. Saag has a U18 from AHRQ examining the safety of biologic agents in Rheumatoid Arthritis and has previously served as the principle investigator and lead author on the 2009 ACR-funded Recommendations for the Treatment of Rheumatoid Arthritis.

Ann C. Miller, MD, Secretary: Dr. Ann Miller has spent over 20 years in biopharma marketing with experience across many therapeutic areas and all phases of the product lifecycle, including in-line brands, launch products, and Phase 2 compounds. After receiving her BA and MD degrees from Duke University, Dr. Miller started her career at Merck and Co., with jobs of increasing responsibility across Medical Affairs, Business Development, and Marketing, including responsibility for the US Fosamax® osteoporosis franchise. In 2002, she moved to Amgen to help build the Global Marketing function, with responsibility for the oncology franchise and, subsequently, the anemia/nephrology franchise. During this time, she received the prestigious IMPACT award for her co-leadership of a two-year, corporate-wide effort to develop and embed Amgen's approach to marketing strategy development. In early 2006, she took over responsibility for the US osteoporosis launch of denosumab, Amgen's key pipeline product. Dr. Miller also served as the Senior Vice President, Pharmaceutical Services, at Eisai Inc., a Japanese biopharma company with roughly \$4B in US sales. Currently, she is Vice President of Marketing at Sanofi.

Dr. Miller was named a senior scholar at Duke's Fuqua School of Business in 2008 and has been an invited speaker on Marketing for the Marketing Sciences Institute, Keck Graduate Institute, and Anderson School of Business (UCLA) Executive Education. She was elected to the National Osteoporosis Foundation Board of Trustees in 2008.

Robert Understein, CPA, Treasurer: Robert Understein is President of the Government Transformation Initiative (GTI) and Manager of the Federal Sector Business Development Practice for McGladrey LLP in Washington, DC. His nearly 50-year career has focused on financial and tax planning, equity placements (real estate and communication properties), commercial real estate financing, and commercial real estate advisory services. Mr. Understein began his career working with Understein and Associates, a family owned business. As a CPA and high-end financial and tax planning firm in the Greater Metro

Washington D.C. area, the firm's clients were among the "Who's Who" of business and political Washington in the late 60's, 70's and 80's. After the practice was sold at the end of the 1980's, Mr. Understein worked with large and mid-sized companies for the next 20 years. In June of 2010, he joined McGladrey as Manager of Business Development on a national level. He currently works with the firm and is transitioning to the Federal Sector Practice.

Mr. Understein holds a BS in Accounting from the University of Virginia in Charlottesville, VA and a JD in Law from Washington College of Law at American University in Washington, DC.